Arana's pilot for arthritis
Wednesday, 26 November, 2008
Arana Therapeutics has sought approval for a small dose regimen study of its lead inflammatory disease candidate ART621 in rheumatoid arthritis.
The study, to be conducted in Sri Lanka and enrolling 20 patients, will compare four different dose regimens in order to optimise the regimen for its international Phase II dose ranging study.
Arana’s acting CEO Dr Steffen Nock said in an ASX statement that the data gathered from the small study will help fine-tune the larger one.
He said data from the company’s study of ART621 in psoriasis was due early next year.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
